Secretory IgA, Inc, Ann Arbor, Michigan, USA.
Preclinical Services, University of North Texas Health Science Center-College of Pharmacy, Fort Worth, Texas, USA.
J Infect Dis. 2021 Oct 28;224(8):1394-1397. doi: 10.1093/infdis/jiab087.
Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model.
同时给予人分泌型免疫球蛋白 A（sIgA）与低剂量万古霉素可提高艰难梭菌感染（CDI）仓鼠模型的存活率。万古霉素（5 或 10mg/kg×5 天）联合健康供体血浆 sIgA/单体 IgA（TID×21 天）或高免疫 sIgA/单体 IgA（BID×13 天）可提高存活率。与万古霉素单独治疗相比，sIgA 分别提高了生存率，对数秩 Mantel-Cox P =.018 和.039，健康和高免疫 sIgA 分别为.018 和.039。口服给予 sIgA（重组人分泌成分加来自混合人血浆的 IgA 二聚体/聚合物）的被动免疫可预防部分治疗的 CDI 仓鼠模型中的死亡。
